|
|
IL-7-Fc |
|
Vaxjo ID |
371 |
|
Vaccine Adjuvant Name |
IL-7-Fc |
|
Adjuvant VO ID |
VO_0005634
|
|
Description |
cytokine adjuvant that induces Th1 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
nonlytic Fc-fused IL-7 (IL-7-Fc(m)) |
|
Preparation |
The human IL-7 gene was also codon-optimized by GenScript and cloned into the pGX10 vector. To genetrate Fc-fused IL-7 constructs, a NheI site was introduced prior to the termination codon of IL-7. To construct either lytic Fc or nonlytic Fc constructs, murine Fcγ2a sequences were codon-optimized by GenScript. To generate nonlytic Fc constructs, site-directed mutagenesis was used to inactivate the C1q binding site (Glu 318, Lys 320, Lys 322 to Ala) and FcγRI binding site (Leu 235 to Glu) |
|
Function |
increased frequency of CD8(+) T cells due to enhanced T-cell proliferation in T-cell priming |
| References |
Nam et al., 2010: Nam HJ, Song MY, Choi DH, Yang SH, Jin HT, Sung YC. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. European journal of immunology. 2010; 40(2); 351-358. [PubMed: 19950168].
|
|
